Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/156538
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Llorach Parés, Laura | - |
dc.contributor.author | Nonell Canals, Alfons | - |
dc.contributor.author | Sánchez Martínez, Melchor | - |
dc.contributor.author | Avila, Conxita | - |
dc.date.accessioned | 2020-04-21T15:47:41Z | - |
dc.date.available | 2020-04-21T15:47:41Z | - |
dc.date.issued | 2018-10-16 | - |
dc.identifier.issn | 1660-3397 | - |
dc.identifier.uri | http://hdl.handle.net/2445/156538 | - |
dc.description.abstract | Alzheimer's disease (AD) is becoming one of the most disturbing health and socioeconomic problems nowadays, as it is a neurodegenerative pathology with no treatment, which is expected to grow further due to population ageing. Actual treatments for AD produce only a modest amelioration of symptoms, although there is a constant ongoing research of new therapeutic strategies oriented to improve the amelioration of the symptoms, and even to completely cure the disease. A principal feature of AD is the presence of neurofibrillary tangles (NFT) induced by the aberrant phosphorylation of the microtubule-associated protein tau in the brains of affected individuals. Glycogen synthetase kinase-3 beta (GSK3β), casein kinase 1 delta (CK1δ), dual-specificity tyrosine phosphorylation regulated kinase 1A (DYRK1A) and dual-specificity kinase cdc2-like kinase 1 (CLK1) have been identified as the principal proteins involved in this process. Due to this, the inhibition of these kinases has been proposed as a plausible therapeutic strategy to fight AD. In this study, we tested in silico the inhibitory activity of different marine natural compounds, as well as newly-designed molecules from some of them, over the mentioned protein kinases, finding some new possible inhibitors with potential therapeutic application. | - |
dc.format.extent | 32 p. | - |
dc.format.mimetype | application/pdf | - |
dc.language.iso | eng | - |
dc.publisher | MDPI | - |
dc.relation.isformatof | Reproducció del document publicat a: https://doi.org/10.3390/md16100386 | - |
dc.relation.ispartof | Marine Drugs, 2018, vol. 16, num. 10, p. 386 | - |
dc.relation.uri | https://doi.org/10.3390/md16100386 | - |
dc.rights | cc-by (c) Llorach Parés, Laura et al., 2018 | - |
dc.rights.uri | http://creativecommons.org/licenses/by/3.0/es | - |
dc.source | Articles publicats en revistes (Biologia Evolutiva, Ecologia i Ciències Ambientals) | - |
dc.subject.classification | Malaltia d'Alzheimer | - |
dc.subject.classification | Disseny de medicaments | - |
dc.subject.other | Alzheimer's disease | - |
dc.subject.other | Drug design | - |
dc.title | Kororamides, convolutamines, and indole derivatives as possible tau and dual specificity kinases inhibitors for Alzheimer's Disease | - |
dc.type | info:eu-repo/semantics/article | - |
dc.type | info:eu-repo/semantics/publishedVersion | - |
dc.identifier.idgrec | 688028 | - |
dc.date.updated | 2020-04-21T15:47:42Z | - |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | - |
Appears in Collections: | Articles publicats en revistes (Biologia Evolutiva, Ecologia i Ciències Ambientals) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
688028.pdf | 5.6 MB | Adobe PDF | View/Open |
This item is licensed under a Creative Commons License